Alpha 2.0
Login Register
» Authors » Roberto Luksch

Roberto Luksch

Explore the profile of Roberto Luksch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 144
Citations 2539
Followers 0
Related Specialties
Oncology
Pediatrics
Hematology
Top 10 Co-Authors
Maura Massimino
Andrea Ferrari
Michela Casanova
Filippo Spreafico
Monica Terenziani
Cristina Meazza
Marta Podda
Elisabetta Schiavello
Veronica Biassoni
Stefano Chiaravalli
Published In
Pediatr Blood Cancer
Tumori
J Clin Oncol
Cancer
Eur J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
Dubois S, Ogawa C, Moreno L, Mosse Y, Fischer M, Ryan A, et al.
Cancer . 2025 Feb; 131(4):e35751. PMID: 39932800
Background: This study evaluated the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine as monotherapy and combination therapy in children with relapsed/refractory neuroblastoma. Methods: Patients aged 2-21 years who had ...
2.
Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review
Amoroso L, Fagioli F, Tondo A, Conte M, Badino C, Di Cataldo A, et al.
Support Care Cancer . 2025 Feb; 33(3):153. PMID: 39907793
Purpose: Patients with high-risk neuroblastoma (HR NB) frequently present with metastases in the bone marrow and bone. Approximately 15% of these patients are refractory to induction therapy, and 50% relapse....
3.
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial
Luksch R, Palmerini E, Milano G, Paioli A, Asaftei S, Barretta F, et al.
Pediatr Blood Cancer . 2025 Jan; 72(4):e31551. PMID: 39833645
Background: Several studies have shown that the intensity of treatment in Ewing sarcoma has an impact on outcome. The present trial tested the non-inferiority of intensive, shorter, induction chemotherapy (25 ...
4.
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype
Massimino M, Barretta F, Dossena C, Minasi S, Buttarelli F, Biassoni V, et al.
Neuro Oncol . 2024 Sep; 27(1):209-218. PMID: 39331528
Background: We applied the strategy for M+ medulloblastoma across all high-risk subgroups, including LC/A histology, TP53 mutations, and MYC/MYCN amplification. Methods: Patients over 3 years old received, after surgery, staging...
5.
Foreign patients and multicultural challenges in pediatric oncology: The experience of the Istituto Nazionale dei Tumori in Milan
Lombardi M, Silva M, Giovanetti M, Cabibbe D, Luksch R, Terenziani M, et al.
Pediatr Blood Cancer . 2024 Aug; 71(11):e31260. PMID: 39138601
This paper describes the complexity of the clinical management of foreign minors suffering from cancer, through the clinical experience of an Italian referral center. The study includes 50 patients less...
6.
Caring for children with cancer evacuated from Ukraine: The patients' perception
Bolognese M, Massimino M, Cabibbe D, Zecca M, Fornara M, Armiraglio M, et al.
Pediatr Blood Cancer . 2024 May; 71(8):e31087. PMID: 38769590
Background And Aims: Since the beginning of the war in Ukraine on February 24, 2022, many pediatric oncology centers welcomed evacuated patients. To better understanding the needs of patients and...
7.
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group
Palassini E, Baldi G, Sulfaro S, Barisella M, Bianchi G, Campanacci D, et al.
Cancer Treat Rev . 2024 Apr; 126:102722. PMID: 38604052
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) clinical practice...
8.
Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Children with High-Risk Neuroblastoma Using a Reduced-Intensity Conditioning Regimen: Results from the AIEOP Trial
Prete A, Lanino E, Saglio F, Biffi A, Calore E, Faraci M, et al.
Transplant Cell Ther . 2024 Mar; 30(5):530.e1-530.e8. PMID: 38460729
Despite aggressive multimodal treatment, the outcomes of pediatric patients with high-risk (HR) neuroblastoma (NB) remain poor. The rationale for allogeneic hematopoietic stem cell transplantation (allo-HCT) to treat NB was based...
9.
From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models
Capasso M, Brignole C, Lasorsa V, Bensa V, Cantalupo S, Sebastiani E, et al.
J Transl Med . 2024 Feb; 22(1):151. PMID: 38351008
Background: Neuroblastoma (NB) represents the most frequent and aggressive form of extracranial solid tumor of infants. Although the overall survival of patients with NB has improved in the last years,...
10.
Local treatment in initially unresected non-rhabdomyosarcoma soft-tissue sarcomas of children and adolescents: A retrospective single-center experience
Ferrari A, Vennarini S, Fiore M, Bergamaschi L, Chiaravalli S, Morosi C, et al.
Pediatr Blood Cancer . 2024 Jan; 71(4):e30901. PMID: 38296840
Background: Pediatric non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) are a heterogeneous group of aggressive tumors. Patients with locally advanced/initially unresected disease represent a subset of patients with unsatisfactory outcome: limited data are...